Baseline variable | Remission group† (n = 30) | Non-remission group (n = 104) | p Value‡ |
---|---|---|---|
Anti-CCP, anti-cyclic citrullinated protein; CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HLA, human leucocyte antigen; RA, rheumatoid arthritis; RF, rheumatoid factor; SHS, Sharp–van der Heijde. | |||
*Except where otherwise indicated, values are the mean (SD). Positive cut-off values were as follows: for IgM RF, ⩾20 IU/ml; for IgA RF, ⩾7 U/ml; for anti-CCP antibodies, ⩾50 U/ml. | |||
†The remission group was defined by patients with RA with DAS<1.6 both at 3 and 5 years. | |||
‡p Values for the comparison of the two groups. | |||
§DRB1*04 includes DRB1*0401, 0404, 0405 and 0408. | |||
¶SHS on radiographic evaluation of the hands and feet. | |||
Women, n(%) | 21 (70) | 81 (77.9) | 0.37 |
Age at RA diagnosis, years | 44.3 (13.9) | 47.8 (11.8) | 0.20 |
Disease duration, months | 6.7 | 9.2 | 0.21 |
HAQ | 1.12 (0.69) | 1.41 (0.70) | 0.04 |
DAS | 3.70 (0.94) | 4.24 (0.72) | 0.002 |
ESR, mm/h | 32.6 (23.5) | 43.5 (29.2) | 0.75 |
CRP, mg/l | 19.8 (25.3) | 40.7 (49.7) | 0.02 |
RF positivity, n (%) | |||
IgM RF | 13 (46.4) | 65 (70) | 0.02 |
IgA RF | 17 (60.7) | 71 (76.3) | 0.10 |
Anti-CCP antibody,n (%) | 12 (48) | 45 (53.6) | 0.62 |
HLA-DRB1*04,n (%) § | 14 (48.3) | 50 (49.5) | 0.91 |
HLA-DRB1*01,n (%) | 9 (31.0) | 29 (28.7) | 0.81 |
Total SHS¶ | 4.67 (9.65) | 5.41 (7.31) | 0.15 |
Erosion SHS¶ | 1.33 (2.63) | 1.87 (3.54) | 0.26 |
Joint-space narrowing SHS¶ | 3.33 (7.46) | 3.54 (5.5) | 0.44 |